“GSK announces NEJM publication of Phase 3b/4 study of ambrisentan and tadalafil as first-line combination treatment in patients with pulmonary arterial hypertension”
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
“GSK today announced the start of a phase III programme to evaluate the efficacy and safety of retosiban, an investigational oxytocin antagonist. Retosiban is being developed as a potential treatment to improve neonatal outcomes of babies born to women in spontaneous preterm labour by prolonging t
1
GSK announces NEJM publication of Phase 3b/4 study of ambrisentan and tadalafil as first-line combination treatment in patients with pulmonary arterial hypertension | GSK
Press releases | GSK
GSK announces start of phase III programme to evaluate retosiban for spontaneous preterm labour | GSK
